A Phase 2 interventional study of Lebrikizumab and Placebo in Asthma, sponsored by Hoffmann-La Roche. Terminated at 45 sites in 15 countries. Open to participants aged 12 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-10.
Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment
Sponsor decision to discontinue lebrikizumab development for the treatment of asthma.
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing lebrikizumab in Asthma — none open to participants now, none under way, none of them phase 3. lebrikizumab · Asthma.
Among the 12 studies testing lebrikizumab in Asthma, this one is the 6th largest by enrollment, is one of 3 that started in 2014, is one of 7 in phase 2, and was the 9th registered.
4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.
Browse Asthma studies →None of the 12 studies testing lebrikizumab in Asthma is open now. The open studies under Asthma, anywhere →
lebrikizumab: first FDA approval 2024 (EBGLYSS), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →
Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.
This study: 12 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 3 started in 2014.
This study's enrollment of 230 is above the median of 79 across 3,344 interventional studies indexed under Asthma.
Median enrollment 224 across the 12 interventional studies. Of the 11 that completed or were terminated, 4 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 12 have an industry lead sponsor. The 2 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
41 studies in Asthma by Hoffmann-La Roche: none open now, none under way, none of them phase 3. Of 39 finished, 16 (41%) have results posted.
Among the 41 studies in Asthma by Hoffmann-La Roche, this one is the 13th largest by enrollment of the 35 interventional ones that give a count, is one of 3 that started in 2014, is one of 19 in phase 2, and was the 32nd registered.
Hoffmann-La Roche’s Asthma studies by the year they started, since 2000.
None of the studies under way reaches primary completion within a year.
Among the 12 studies testing lebrikizumab in Asthma, from their registry updates:
Among Hoffmann-La Roche’s 41 in Asthma:
This tab as a report to print or save as PDF → With an account.
This randomized, multicenter, double-blind, placebo-controlled, parallel-group study will evaluate the efficacy of lebrikizumab compared with placebo, as measured by the ability of participants to achieve lower daily doses of OCS, among those with severe corticosteroid-dependent asthma. Prednisone/prednisolone will be the OCS therapy prescribed. Participants will be randomized to receive lebrikizumab or matching placebo for 44 weeks in a double-blind, placebo-controlled (DBPC) period. Those who complete the 44-week period may continue into a 32-week active treatment extension (ATE) period, during which all participants will receive lebrikizumab treatment. Following completion of the ATE period, participants who have both tolerated and derived benefit from treatment with lebrikizumab may continue their lebrikizumab treatment into a long-term extension (LTE) period. Participants will transition to 24 weeks of safety follow-up upon discontinuation of study drug.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive lebrikizumab at high dose level as subcutaneous (SC) injection every 4 weeks during the 44-week DBPC period, followed by a 32-week ATE period, and during the LTE period.
Drug: Lebrikizumab
Participants will receive lebrikizumab at low dose level as SC injection every 4 weeks during the 44-week DBPC period, followed by a 32-week ATE period, and during the LTE period.
Drug: Lebrikizumab
Participants will receive placebo matching to lebrikizumab SC injection every 4 weeks during the 44-week DBPC period. Participants will then be randomized to receive either high- or low-dose lebrikizumab every 4 weeks during the 32-week ATE period and will continue same treatment in the LTE period.
Drug: Lebrikizumab · Drug: Placebo
Lebrikizumab will be administered as SC injections every 4 weeks at dose and schedule described in arm description.
Also known as: RO5490255
Placebo matching to lebrikizumab will be administered as SC injections every 4 weeks as per schedule described in arm description.
Percent Change From Baseline in Daily Oral Corticosteroid (OCS) Dose at Week 44
OCS used in study: prednisone/prednisolone. Participants entered their total daily use of OCS into an electronic diary (eDiary) on a daily basis. The OCS intake since the previous study visit and the prescribed OCS dose for the next 28 days was captured by physician on a dedicated page in the electronic Case Report Form (eCRF). Baseline OCS dose was calculated using the eDiary as average daily dose over 28 days prior to randomization. Post-baseline OCS dose was obtained from the eCRF and calculated as average daily dose over the 28 days preceding the timepoint. Percent change = (post-baseline value - baseline value)/baseline value \* 100.
Time frame: Baseline (including 28 days prior to Day 1), Week 44 (including 28 days prior to Week 44)
Absolute Change From Baseline in Daily OCS Dose at Week 44
OCS used in study: prednisone/prednisolone. Participants entered their total daily use of OCS into an eDiary on a daily basis. The OCS intake since the previous study visit and the prescribed OCS dose for the next 28 days was captured by physician on a dedicated page in the eCRF. Baseline OCS dose was calculated using the eDiary as average daily dose over 28 days prior to randomization. Post baseline OCS dose was obtained from the eCRF and calculated as average daily dose over the 28 days preceding the timepoint.
Time frame: Baseline (including 28 days prior to Day 1), Week 44 (including 28 days prior to Week 44)
Percent Change From Week 12 in Daily OCS Dose at Week 44
OCS used in study: prednisone/prednisolone. Participants entered their total daily use of OCS into an eDiary on a daily basis. The OCS intake since the previous study visit and the prescribed OCS dose for the next 28 days was captured by physician on a dedicated page in the eCRF. OCS dose at a timepoint was obtained from the eCRF and calculated as average daily dose over the 28 days preceding the timepoint. Percent change = (value at Week 44 - value at Week 12)/value at Week 12 \* 100. Reported values are adjusted mean values obtained from MMRM analysis.
Time frame: Week 12 (including 28 days prior to Week 12), Week 44 (including 28 days prior to Week 44)
Percentage of Participants Who Achieved at Least a 50 Percent (%) Reduction in Their Daily OCS Dose at Week 44 Relative to Baseline
OCS used in study: prednisone/prednisolone. Participants entered their total daily use of OCS into an eDiary on a daily basis. The OCS intake since the previous study visit and the prescribed OCS dose for the next 28 days was captured by physician on a dedicated page in the eCRF. Baseline OCS dose was calculated using the eDiary as average daily dose over 28 days prior to randomization. Post baseline OCS dose was obtained from the eCRF and calculated as average daily dose over the 28 days preceding the timepoint. The 95% confidence interval (CI) for the percentage was based on normal approximation for binomial proportion.
Time frame: Baseline (including 28 days prior to Day 1), Week 44 (including 28 days prior to Week 44)
Percentage of Participants Who Either Discontinued OCS Therapy or Achieved an Adrenal Maintenance Dose at Week 44
Percentage of participants who either discontinued OCS therapy or have achieved an adrenal maintenance dose is reported. Identification of participants achieving adrenal maintenance dose was based on physician assessment recorded in eCRF in the presence of cortisol = 100 nanomoles per liter (nmol/L). The 95% CI for the percentage was based on normal approximation for binomial proportion.
Time frame: Week 44
Rate of Asthma Exacerbations During the 44-Week Double-Blind Placebo Controlled (DBPC) Period
An asthma exacerbation is defined as new or increased asthma symptoms (including wheeze, cough, dyspnea, chest tightness, and/or night-time awakening due to these symptoms) that lead to treatment with systemic corticosteroids or to hospitalization. Treatment with systemic corticosteroids is defined as treatment with oral, intravenous (IV), or intramuscular (IM) corticosteroids for at least 3 days or an emergency department visit with at least 1 dose of IV or IM corticosteroids. Rate of asthma exacerbation = total number of exacerbation events divided by total follow-up time in patient years.
Time frame: Baseline up to Week 44
| Milestone | Placebo | Lebrikizumab 125 mg | Lebrikizumab 250 mg | Placebo/Lebrikizumab 125 mg | Placebo/Lebrikizumab 250 mg |
|---|---|---|---|---|---|
| Started | 56 | 56 | 72 | 24 | 22 |
| Completed | 48 | 39 | 51 | 18 | 19 |
| Not completed | 8 | 17 | 21 | 6 | 3 |
| Withdrew: Adverse event | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Study terminated by sponsor | 1 | 1 | 3 | 1 | 0 |
| Withdrew: Withdrawal by subject | 5 | 10 | 16 | 4 | 2 |
| Withdrew: Physician decision | 1 | 0 | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Non-compliance | 0 | 1 | 1 | 0 | 0 |
| Withdrew: Other | 0 | 4 | 0 | 1 | 1 |
OCS used in study: prednisone/prednisolone. Participants entered their total daily use of OCS into an electronic diary (eDiary) on a daily basis. The OCS intake since the previous study visit and the prescribed OCS dose for the next 28 days was captured by physician on a dedicated page in the electronic Case Report Form (eCRF). Baseline OCS dose was calculated using the eDiary as average daily dose over 28 days prior to randomization. Post-baseline OCS dose was obtained from the eCRF and calculated as average daily dose over the 28 days preceding the timepoint. Percent change = (post-baseline value - baseline value)/baseline value \* 100.
| percent change | Placebo | Lebrikizumab 125 mg | Lebrikizumab 250 mg |
|---|---|---|---|
| Percent Change From Baseline in Daily Oral Corticosteroid (OCS) Dose at Week 44 | -36.4 ± 5.99 | -42.9 ± 8.69 | -38.6 ± 7.24 |
OCS used in study: prednisone/prednisolone. Participants entered their total daily use of OCS into an eDiary on a daily basis. The OCS intake since the previous study visit and the prescribed OCS dose for the next 28 days was captured by physician on a dedicated page in the eCRF. Baseline OCS dose was calculated using the eDiary as average daily dose over 28 days prior to randomization. Post baseline OCS dose was obtained from the eCRF and calculated as average daily dose over the 28 days preceding the timepoint.
| mg | Placebo | Lebrikizumab 125 mg | Lebrikizumab 250 mg |
|---|---|---|---|
| Absolute Change From Baseline in Daily OCS Dose at Week 44 | -5.2 ± 0.82 | -6.6 ± 1.18 | -5.8 ± 0.99 |
OCS used in study: prednisone/prednisolone. Participants entered their total daily use of OCS into an eDiary on a daily basis. The OCS intake since the previous study visit and the prescribed OCS dose for the next 28 days was captured by physician on a dedicated page in the eCRF. OCS dose at a timepoint was obtained from the eCRF and calculated as average daily dose over the 28 days preceding the timepoint. Percent change = (value at Week 44 - value at Week 12)/value at Week 12 \* 100. Reported values are adjusted mean values obtained from MMRM analysis.
| percent change | Placebo | Lebrikizumab 125 mg | Lebrikizumab 250 mg |
|---|---|---|---|
| Percent Change From Week 12 in Daily OCS Dose at Week 44 | -36.3 ± 5.69 | -44.0 ± 8.47 | -37.8 ± 6.97 |
OCS used in study: prednisone/prednisolone. Participants entered their total daily use of OCS into an eDiary on a daily basis. The OCS intake since the previous study visit and the prescribed OCS dose for the next 28 days was captured by physician on a dedicated page in the eCRF. Baseline OCS dose was calculated using the eDiary as average daily dose over 28 days prior to randomization. Post baseline OCS dose was obtained from the eCRF and calculated as average daily dose over the 28 days preceding the timepoint. The 95% confidence interval (CI) for the percentage was based on normal approximation for binomial proportion.
| percentage of participants | Placebo | Lebrikizumab 125 mg | Lebrikizumab 250 mg |
|---|---|---|---|
| Percentage of Participants Who Achieved at Least a 50 Percent (%) Reduction in Their Daily OCS Dose at Week 44 Relative to Baseline | 39.6 ± 29.8 | 30.4 ± 18.3 | 40.9 ± 29.0 |
Percentage of participants who either discontinued OCS therapy or have achieved an adrenal maintenance dose is reported. Identification of participants achieving adrenal maintenance dose was based on physician assessment recorded in eCRF in the presence of cortisol = 100 nanomoles per liter (nmol/L). The 95% CI for the percentage was based on normal approximation for binomial proportion.
| percentage of participants | Placebo | Lebrikizumab 125 mg | Lebrikizumab 250 mg |
|---|---|---|---|
| Percentage of Participants Who Either Discontinued OCS Therapy or Achieved an Adrenal Maintenance Dose at Week 44 | 11.5 ± 5.1 | 10.7 ± 2.6 | 9.1 ± 2.2 |
An asthma exacerbation is defined as new or increased asthma symptoms (including wheeze, cough, dyspnea, chest tightness, and/or night-time awakening due to these symptoms) that lead to treatment with systemic corticosteroids or to hospitalization. Treatment with systemic corticosteroids is defined as treatment with oral, intravenous (IV), or intramuscular (IM) corticosteroids for at least 3 days or an emergency department visit with at least 1 dose of IV or IM corticosteroids. Rate of asthma exacerbation = total number of exacerbation events divided by total follow-up time in patient years.
| events per patient year | Placebo | Lebrikizumab 125 mg | Lebrikizumab 250 mg |
|---|---|---|---|
| Rate of Asthma Exacerbations During the 44-Week Double-Blind Placebo Controlled (DBPC) Period | 1.78 | 1.54 | 1.47 |
Collected over Placebo group: from first dose of study treatment up to Week 44; Placebo/Lebrikizumab 125 mg and 250 mg groups: from Week 45 (first dose of lebrikizumab) up to end of treatment extension (up to 83 weeks); Lebrikizumab 125 mg and 250 mg groups: from first dose of study treatment up to end of treatment extension (up to 120 weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/102 (0%) | 21/102 (20.6%) | 82/102 (80.4%) |
| Placebo/Lebrikizumab 125 mg | 0/24 (0%) | 4/24 (16.7%) | 22/24 (91.7%) |
| Placebo/Lebrikizumab 250 mg | 0/22 (0%) | 1/22 (4.5%) | 19/22 (86.4%) |
| Lebrikizumab 125 mg | 1/56 (1.8%) | 6/56 (10.7%) | 47/56 (83.9%) |
| Lebrikizumab 250 mg | 0/72 (0%) | 27/72 (37.5%) | 60/72 (83.3%) |
| Event | Placebo | Placebo/Lebrikizumab 125 mg | Placebo/Lebrikizumab 250 mg | Lebrikizumab 125 mg | Lebrikizumab 250 mg |
|---|---|---|---|---|---|
| AsthmaRespiratory, thoracic and mediastinal disorders | 11/102 | 0/24 | 0/22 | 0/56 | 10/72 |
| Anaphylactic reactionImmune system disorders | 0/102 | 0/24 | 1/22 | 1/56 | 0/72 |
| GastritisGastrointestinal disorders | 0/102 | 1/24 | 0/22 | 0/56 | 0/72 |
| VomitingGastrointestinal disorders | 0/102 | 1/24 | 0/22 | 0/56 | 0/72 |
| Postoperative renal failureInjury, poisoning and procedural complications | 0/102 | 1/24 | 0/22 | 0/56 | 0/72 |
| HaemangiomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/102 | 1/24 | 0/22 | 0/56 | 0/72 |
| HeadacheNervous system disorders | 0/102 | 1/24 | 0/22 | 0/56 | 0/72 |
| ParaesthesiaNervous system disorders | 0/102 | 1/24 | 0/22 | 0/56 | 0/72 |
| SpondylolisthesisMusculoskeletal and connective tissue disorders | 0/102 | 1/24 | 0/22 | 0/56 | 0/72 |
| ColitisGastrointestinal disorders | 0/102 | 0/24 | 0/22 | 0/56 | 2/72 |
| Event | Placebo | Placebo/Lebrikizumab 125 mg | Placebo/Lebrikizumab 250 mg | Lebrikizumab 125 mg | Lebrikizumab 250 mg |
|---|---|---|---|---|---|
| AsthmaRespiratory, thoracic and mediastinal disorders | 71/102 | 14/24 | 16/22 | 38/56 | 47/72 |
| Lower respiratory tract infectionInfections and infestations | 25/102 | 8/24 | 14/22 | 7/56 | 27/72 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 8/102 | 4/24 | 8/22 | 3/56 | 10/72 |
| FallInjury, poisoning and procedural complications | 1/102 | 0/24 | 5/22 | 0/56 | 5/72 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 2/102 | 1/24 | 4/22 | 3/56 | 3/72 |
| HeadacheNervous system disorders | 11/102 | 2/24 | 1/22 | 6/56 | 13/72 |
| NasopharyngitisInfections and infestations | 7/102 | 4/24 | 1/22 | 8/56 | 8/72 |
| CoughRespiratory, thoracic and mediastinal disorders | 5/102 | 4/24 | 3/22 | 2/56 | 6/72 |
| BronchitisInfections and infestations | 5/102 | 0/24 | 1/22 | 9/56 | 1/72 |
| Peripheral swellingGeneral disorders | 2/102 | 0/24 | 3/22 | 0/56 | 3/72 |
The modified intent-to-treat (miTT) population included all participants who were randomized and received at least one dose of study drug (lebrikizumab or placebo).
| Age, Continuous(years) | Placebo | Lebrikizumab 125 mg | Lebrikizumab 250 mg | Total |
|---|---|---|---|---|
| Mean | 49.1 ± 14.0 | 54.2 ± 12.2 | 49.1 ± 15.5 | 50.3 ± 14.2 |
| Age, Customized(Participants) | Placebo | Lebrikizumab 125 mg | Lebrikizumab 250 mg | Total |
|---|---|---|---|---|
| 12 to < 18 | 6 | 0 | 6 | 12 |
| 18 to < 30 | 5 | 2 | 3 | 10 |
| 30 to < 50 | 30 | 12 | 21 | 63 |
| 50 to < 65 | 51 | 32 | 34 | 117 |
| > = 65 | 10 | 10 | 8 | 28 |
| Sex: Female, Male(Participants) | Placebo | Lebrikizumab 125 mg | Lebrikizumab 250 mg | Total |
|---|---|---|---|---|
| Female | 55 | 36 | 44 | 135 |
| Male | 47 | 20 | 28 | 95 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | Lebrikizumab 125 mg | Lebrikizumab 250 mg | Total |
|---|---|---|---|---|
| Hispanic or Latino | 5 | 2 | 5 | 12 |
| Not Hispanic or Latino | 97 | 54 | 67 | 218 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Placebo | Lebrikizumab 125 mg | Lebrikizumab 250 mg | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 6 | 1 | 6 | 13 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 2 | 1 | 0 | 3 |
| White | 91 | 54 | 64 | 209 |
| More than one race | 3 | 0 | 1 | 4 |
| Unknown or Not Reported | 0 | 0 | 1 | 1 |
Ran from Feb 2014 to primary completion in Dec 2016, 33 months.
Results were first posted in Nov 2026, 9 years 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
Sponsor decision to discontinue lebrikizumab development for the treatment of asthma.
Sponsor decision to discontinue lebrikizumab development for the treatment of asthma.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is terminated, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lebrikizumab